In a 71-week, double-blind study, Nova Nordisk—creators of the popular weight loss drug Wegovy—says their oral semaglutide ...

Shrotriya described India's obesity drug uptake as "just the tip of the iceberg," pointing to widespread prevalence across ...

Novo Nordisk has cut prices of its weight-loss drug Wegovy by up to 37% in India. This move intensifies competition with Eli ...

Oregon and federal leaders must take a dual approach: Expanding safe, affordable access to FDA-approved anti-obesity ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

Novo Nordisk shares rose Monday after the Danish drugmaker withdrew from a bidding war with Pfizer for U.S. obesity drug maker Metsera. Shares climbed as much as 3.5% in early European trade. Pfizer ...

CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®) Results include a 9.3% weight reduction with CAM2056 vs. 5.2% with weekly semaglutide at ...

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new ...

Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...